LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced that results of an ...
Zacks.com on MSN
BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down
Shares of Bausch Health BHC were down 1.86% on Jan. 26. This was the second consecutive session when shares slid. BHC stock ...
Clinical Trials Arena on MSN
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials
Rifaximin SSD failed to significantly delay the onset of HE in patients with liver cirrhosis, but Bausch is yet to scrap the molecule’s development.
An international team of researchers has found that an antibiotic commonly prescribed for patients with liver disease, called rifaximin, has led to the global emergence of an almost untreatable form ...
Please provide your email address to receive an email when new articles are posted on . Patients who received simvastatin plus rifaximin experienced similar rates of complications as those treated ...
Rifaximin improves the gut microenvironment by reducing the abundance of harmful bacteria while increasing probiotic bacteria. It inhibits the translocation of bacteria from the mouth to the intestine ...
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results